Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.
about
Pharmacogenomic discovery using cell-based modelsEffectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program.Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancerEfficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea.Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropeniaCell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivityLymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationDocetaxel in advanced non-small cell lung cancer.Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer.Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid TumoursRace does not explain genetic heterogeneity in pharmacogenomic pathways.Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations.Effect of population and gender on chemotherapeutic agent-induced cytotoxicity.S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysisDocetaxel in the treatment of advanced non-small-cell lung cancer.VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans.Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy.Classical twin design in modern pharmacogenomics studies.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy.Race and ethnicity in cancer therapy: what have we learned?Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.Pharmacogenomic diversity in Singaporean populations and Europeans.
P2860
Q28392982-E7889D34-3ABE-4E19-98D6-4A8EB8BE4A7FQ30847864-783D23E8-C9BC-4CDF-B16E-407E37A5F0B8Q33390996-4CB33CDE-1B1D-464A-89D7-713B6BAA56C0Q33566975-A56F9355-BF4D-4913-9243-6246EABA9593Q33766472-4DB41B7D-9BBB-41F5-9BF2-A0DE989ABC0BQ33932736-9D668B01-B409-4B13-B54A-609036C9BF66Q34403621-38DCA188-7B33-4DEF-A4B8-D8B20EA01BC2Q34789161-E7F427F6-90B6-4E1B-8F45-17EAF73BDCF6Q34816784-A3EAC625-F320-420B-8E3D-7E0AA8E919D2Q35068272-4D7D564F-A93E-41FA-B085-EA8377EDA95DQ35799841-400920E6-9307-4A06-B1F0-94B208017F75Q36066126-D7ACEA14-9B56-4962-8AC7-1CD33CB72F59Q36622084-A1CD6B49-2FEB-44F1-BC81-18F57357671FQ36659012-908D25F8-C784-496F-94F1-5B9B36893672Q36762853-04BDAAF8-8A7E-455B-B4EC-3056F9084504Q37000818-B9792B24-5582-41B1-8954-F9DE20E3CBFEQ37076675-F73695F3-18E5-4B38-BC9E-146BF8C1AD83Q37149646-F60EF431-2ABD-44C5-9766-A355200FA38AQ37159518-8DBB043F-9866-41FE-B7E4-33A6CF818936Q37182236-5B417B8D-FCA9-4222-949C-9BAD5DD64AB3Q37242661-284FF0AA-B7B0-488A-B444-E039253D912DQ37274628-F939F1E7-3BB8-446A-B36D-0D7517303780Q37344425-CFEB1778-CB1F-41DB-ABFD-0869AAB9D745Q37414536-0EFE83D3-C293-49D6-BC14-482C226B198AQ37688053-BC0D3E66-6430-46D3-A843-E59CBFDB959BQ37939200-4286A033-6D73-46B1-876F-E305FDD1C0F5Q38003669-3AB24CA0-38DB-4E7D-ACC0-8FD907C1E733Q38178095-64E0DB25-A44B-42EF-B02B-9D33D0AD7189Q39262358-08F24442-D174-4E87-B0EE-03E418DBB448Q39714590-F456BC14-5C97-4B4F-8C68-6585F773304FQ40100374-C5F3B9D3-0137-41CE-A69C-D5846CAA5FF0Q41897007-24C0307C-F782-4808-8DCD-73E722F522FFQ43906898-A5A5FFCF-9B58-44D5-8648-80E2B9F2124FQ53541756-A881DFFA-775D-4524-92D6-697F7ED62DED
P2860
Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Docetaxel and carboplatin is a ...... Caucasian and Asian patients.
@ast
Docetaxel and carboplatin is a ...... Caucasian and Asian patients.
@en
type
label
Docetaxel and carboplatin is a ...... Caucasian and Asian patients.
@ast
Docetaxel and carboplatin is a ...... Caucasian and Asian patients.
@en
prefLabel
Docetaxel and carboplatin is a ...... Caucasian and Asian patients.
@ast
Docetaxel and carboplatin is a ...... Caucasian and Asian patients.
@en
P2093
P356
P1433
P1476
Docetaxel and carboplatin is a ...... n Caucasian and Asian patients
@en
P2093
J F Bishop
M J Millward
P304
P356
10.1093/ANNONC/MDG118
P577
2003-03-01T00:00:00Z